Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Condition:   Respiratory Syncytial Virus Infections Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials